AbbVie 2020: Company Background, Recent Earnings Review, Company Forecast, Company Profile and Clinical Trial Overview

News provided by

Jul 07, 2020, 07:00 ET

DUBLIN, July 7, 2020 /PRNewswire/ -- The "AbbVie" company profile has been added to ResearchAndMarkets.com's offering.

This report explores AbbVie's prescription pharmaceutical performance and outlook over 2019-2029.

Declines in AbbVie's flagship product Humira due to biosimilar competition will be offset by the company's robust portfolio of launch drugs.

Key Themes

[1] Biosimilar launches in Europe and other international markets have negatively impacted Humira's growth, but the brand could grow in 2020 and should have revenue stability until US biosimilar launches in 2023
[2] AbbVie will see tremendous growth from Imbruvica, Skyrizi, Rinvoq, and Venclexta
[3] Acquisition of Allergan, poised to close in 2020, will further diversify AbbVie's revenues

Model Updates (25 February 2020)

Humira forecast adjusted higher due to stronger US trends only partially offset by continued biosimilar impact internationally
Skyrizi forecast adjusted higher due to strong initial launch in moderate-to-severe plaque psoriasis
Rinvoq forecast adjusted lower in the near-term due to launch trend in moderate-to-severe rheumatoid arthritis
Imbruvica forecast adjusted higher due to continued share gains in all lines of therapy in chronic lymphocytic leukemia and all approved indications
Venclexta forecast adjusted lower due to improved forecast for Imbruvica and market trends in chronic lymphocytic leukemia
Mavyret forecast adjusted lower due to lower treated patient volumes and increased competition in the US
Orilissa forecast adjusted higher due to contribution from potential uterine fibroids label expansion
Veliparib forecast pushed out to align with timeline for regulatory submission
Navitoclax forecast added
ABBV-951 forecast added.

Model Updates (8 November 2019)

Humira forecast adjusted lower internationally due to continued biosimilar impact
Skyrizi forecast adjusted higher due to robust launch in the US; international forecast adjusted lower due to slower launch in the five major EU markets and Rest of World
Upadacitinib name changed to Rinvoq
Imbruvica forecast adjusted higher globally due to recent inflection in market share in first-line CLL.

Model Updates (29 July 2019)

Humira sales adjusted lower due to size of biosimilar impact in the five major EU markets and Rest of World regions
Skyrizi sales adjusted higher due to pace of product launch
Mavyret sales adjusted significantly lower due to declining markets and pricing pressure in international geographies
Orilissa sales adjusted lower due to slower initial product ramp
Rova-T forecast removed due to disappointing safety and efficacy data from Phase II TRINITY study
Upadacitinib launch forecast updated
Atrasentan forecast removed.

Key Topics Covered

1. Company Background

Company Overview
Key Metrics
SWOT Analysis
Key Drug & Company Information
Company Comparison

2. Recent Earnings Review

Earnings Overview
Notable Quotes & Important Topics
Pharma Insights Analysis

3. Company Forecast

Prescription Pharmaceuticals Sales Outlook
Branded Drug Outlook
Launch Profile Outlook
Therapy Area Outlook
Regional Sales Outlook
Lifecycle Analysis

4. Company Profile

Marketed & Pipeline Drugs
Recent Events & Analyst Opinions
Upcoming Catalysts
Recent Insights

5. Clinical Trial Overview

Clinical Trial Snapshot
Clinical Trials by Country
Clinical Trials by Status and Phase
Clinical Trials by Drug

For more information about this company profile visit https://www.researchandmarkets.com/r/6rdauq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets